Tania Dempsey, MD, discusses mast cell activation syndrome., which may be a consideration if a patient has not responded to anything else. Simple methods for treating and assessing patients are discussed.
In this detailed webinar on systemic mastocytosis, Dr. Miti introduces Professor Prithviraj Bose, an expert in the field, who discusses the complexities of diagnosing and managing systemic mastocytosis…
Presented by the Florida Society of Clinical Oncology, this program provides opportunities for patients and caregivers to learn and share information regarding a diagnosis of systemic mastocytosis. Pankit…
In an interview conducted at the 2024 Congress of the European Hematology Association in Madrid, Spain, Lindsay Rein, MD, Duke University Medical Center, Durham, North Carolina, provided insights…
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
Systemic mastocytosis with associated hematologic neoplasm (SM-AHN) presents unique diagnostic and treatment challenges. In this Medscape-certified activity, experts discuss the complex patient journey, from delayed diagnosis to individualized…
Systemic mastocytosis, a rare blood disorder, affects the entire body. There are many challenges associated with living with this systemic mastocytosis that are centered around reducing the frequency…
